Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.05.16
Views: 2365

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA

Dr Thomas Dubensky speaks with ecancertv at AACR 2016 about ADUS100, a STING inhibitor, to treat cancer in mouse models, with human trials coming soon.

Stimulator of interferon genes (STING) has key functions in host immunity, stimulating interferon secretion, recruiting a host of other immune cells, and Dr Dubensky additionally reports some links to autoimmune disease.

Having elucidated dose response curves in previous models, he outlines aspects of upcoming trials, including STING-mediated interferon β transcription in melanomas and cancer types to target.

A potential outcome of targeting STING pathways is to stimulate inflammatory responses in the microenvironment, which could be a further target of checkpoint inhibition.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation